Purpose
Design
Participants
Methods
Main Outcome Measures
Results
Conclusions
Keywords
Abbreviations and Acronyms:
AI (artificial intelligence), AMD (age-related macular degeneration), CST (central subfield thickness), ELM (external limiting membrane), fvPED (fibrovascular pigment epithelium detachment), HRF (hyperreflective foci), IRF (intraretinal fluid), MNV (macular neovascularization), NSR (neurosensory retina), PED (pigment epithelium detachment), RPE (retinal pigment epithelium), sPED (serous pigment epithelial detachment), SD (standard deviation), SRF (subretinal fluid), SHRM (subretinal hyperreflective material), 3D (3-dimensional), VA (visual acuity), VEGF (vascular endothelial growth factor)Methods
Dataset
Segmentation Network
Statistical Analysis
Results
First-Treated Eye | Second-Treated Eye | |
---|---|---|
No. of eyes | 2473 | 493 |
Gender | ||
Female (%) | 1493 (60.4) | 342 (69.4) |
Male (%) | 980 (39.6) | 151 (30.6) |
Race/Ethnicity | ||
White (%) | 1319 (53.3) | 290 (58.8) |
Asian (%) | 257 (10.4) | 40 (8.1) |
Black (%) | 57 (2.3) | 5 (1.0) |
Other/Unknown (%) | 840 (34.0) | 158 (32.0) |
Age (yrs) | ||
Mean (SD) | 79.3 (8.6) | 81.4 (7.9) |
50–59 (%) | 60 (2.4) | 3 (0.6) |
60–69 (%) | 289 (11.7) | 40 (8.1) |
70–79 (%) | 791 (32.0) | 139 (28.2) |
≥80 (%) | 1332 (53.9) | 311 (63.1) |
VA (ETDRS letters) | ||
Mean (SD) | 54.0 (16.1) | 62.5 (13.2) |
0–35 (%) | 385 (15.6) | 27 (5.5) |
36–52 (%) | 506 (20.5) | 64 (13.0) |
5369 (%) | 885 (35.8) | 202 (41.0) |
≥70 (%) | 471 (19.0) | 194 (39.4) |
Unknown VA (%) | 226 (9.2) | 6 (1.2) |

Segmented Feature | Mean (SD) at First Injection | Median (IQR) at First Injection | Mann–Whitney U Test P Value | ||
---|---|---|---|---|---|
First-Treated Eye | Second-Treated Eye | First-Treated Eye | Second-Treated Eye | ||
NSR volume (mm3) | 9.485 (1.013) | 9.269 (0.775) | 9.445 (8.905–9.983) | 9.306 (8.790–9.767) | <0.001 |
RPE volume (mm3) | 0.806 (0.094) | 0.794 (0.088) | 0.808 (0.763–0.857) | 0.800 (0.755–0.845) | 0.002 |
IRF volume (mm3) | 0.118 (0.309) | 0.073 (0.196) | 0.007 (0.000–0.090) | 0.003 (0.000–0.049) | <0.001 |
SRF volume (mm3) | 0.455 (0.733) | 0.258 (0.532) | 0.183 (0.022–0.562) | 0.054 (0.006–0.252) | <0.001 |
SHRM volume (mm3) | 0.380 (0.661) | 0.148 (0.283) | 0.135 (0.024–0.445) | 0.054 (0.007–0.186) | <0.001 |
HRF volume (mm3) | 0.003 (0.008) | 0.002 (0.006) | 0.001 (0.000–0.002) | 0.001 (0.000–0.002) | 0.318 |
Drusen volume (mm3) | 0.036 (0.085) | 0.060 (0.080) | 0.010 (0.002–0.036) | 0.031 (0.009–0.080) | <0.001 |
fvPED volume (mm3) | 0.765 (1.305) | 0.491 (0.935) | 0.283 (0.089–0.815) | 0.200 (0.062–0.523) | <0.001 |
sPED volume (mm3) | 0.004 (0.023) | 0.002 (0.012) | 0.000 (0.000–0.001) | 0.000 (0.000–0.000) | <0.001 |
CST (μm) | 347.1 (114.3) | 306.1 (85.1) | 325.8 (266.6–405.0) | 295.0 (253.9–340.3) | <0.001 |

First-Treated versus Second-Treated Eyes
Correlations between Segmented Features

Volumes and Visual Acuity

Volumes (X), Visual Acuity (Y) | Linear Regression (Ordinary Least Squares) | Spearman’s Rank | ||||
---|---|---|---|---|---|---|
R2 | Coefficient | Intercept | P Value | rs | P Value | |
CST | 0.107 | −0.045 | 69.855 | <0.001∗ | −0.306 | <0.001∗ |
SHRM | 0.082 | −7.013 | 56.616 | <0.001∗ | −0.380 | <0.001∗ |
IRF | 0.054 | −11.939 | 55.410 | <0.001∗ | −0.347 | <0.001∗ |
RPE | 0.027 | 30.273 | 29.548 | <0.001∗ | 0.169 | <0.001∗ |
fvPED | 0.022 | −1.824 | 55.389 | <0.001∗ | −0.210 | <0.001∗ |
NSR | 0.015 | −1.957 | 72.530 | <0.001∗ | −0.088 | <0.001∗ |
SRF | 0.008 | −1.947 | 54.866 | <0.001∗ | −0.090 | <0.001∗ |
Drusen | 0.008 | 16.637 | 53.370 | <0.001∗ | 0.144 | <0.001∗ |
HRF | 0.005 | −141.423 | 54.456 | <0.001∗ | −0.092 | <0.001∗ |
sPED | 0.005 | 50.395 | 53.753 | <0.001∗ | 0.134 | <0.001∗ |
Age (X), Volumes (Y) | Linear Regression (Ordinary Least Squares) | Spearman’s Rank | ||||
R2 | Coefficient | Intercept | P Value | rs | P Value | |
RPE | 0.061 | −0.003 | 1.005 | <0.001∗ | −0.257 | <0.001∗ |
sPED | 0.013 | 0.000 | 0.028 | <0.001∗ | −0.218 | <0.001∗ |
NSR | 0.010 | −0.012 | 10.415 | <0.001∗ | −0.114 | <0.001∗ |
SRF | 0.006 | −0.007 | 0.988 | <0.001∗ | −0.140 | <0.001∗ |
IRF | 0.004 | 0.002 | −0.069 | 0.001∗ | 0.171 | <0.001∗ |
HRF | 0.001 | 0.000 | 0.001 | 0.064 | 0.056 | 0.005 |
fvPED | 0.001 | −0.004 | 1.091 | 0.178 | 0.020 | 0.323 |
SHRM | 0.001 | 0.002 | 0.223 | 0.200 | 0.026 | 0.203 |
CST | 0.000 | −0.234 | 372.987 | 0.391 | −0.011 | 0.578 |
Drusen | 0.000 | 0.000 | 0.028 | 0.603 | 0.117 | <0.001∗ |
Volumes (X), Visual Acuity (y) | Linear Regression (Ordinary Least Squares) | Spearman’s Rank | ||||
---|---|---|---|---|---|---|
R2 | Coefficient | Intercept | P Value | rs | P Value | |
SHRM | 0.122 | −16.23 | 64.976 | <0.001 | −0.293 | <0.001 |
RPE | 0.067 | 39.859 | 30.888 | <0.001 | 0.239 | <0.001 |
CST | 0.024 | −0.02 | 69.932 | <0.001 | −0.152 | 0.001 |
IRF | 0.023 | −10.17 | 63.315 | <0.001 | −0.224 | <0.001 |
fvPED | 0.020 | −2.00 | 63.549 | 0.002 | −0.142 | 0.002 |
NSR | 0.016 | 2.20 | 42.140 | 0.006 | 0.114 | 0.012 |
SRF | 0.014 | −2.89 | 63.318 | 0.010 | −0.020 | 0.659 |
Drusen | 0.010 | 16.72 | 61.573 | 0.028 | 0.118 | 0.009 |
HRF | 0.004 | −139.85 | 62.853 | 0.170 | −0.089 | −0.089 |
sPED | 0.002 | 47.21 | 62.466 | 0.354 | 0.136 | 0.003 |
Age (X), Volumes (y) | Linear Regression (Ordinary Least Squares) | Spearman’s Rank | ||||
R2 | Coefficient | Intercept | P Value | rs | P Value | |
RPE | 0.031 | −0.002 | 0.952 | <0.001 | −0.245 | <0.001 |
NSR | 0.031 | −0.017 | 10.670 | <0.001 | −0.171 | <0.001 |
IRF | 0.014 | 0.003 | −0.167 | 0.008 | 0.190 | <0.001 |
sPED | 0.013 | 0.000 | 0.016 | 0.011 | −0.209 | <0.001 |
SRF | 0.012 | −0.007 | 0.849 | 0.016 | −0.174 | <0.001 |
fvPED | 0.009 | −0.011 | 1.398 | 0.036 | −0.111 | 0.014 |
CST | 0.002 | −0.445 | 348.885 | 0.367 | −0.031 | 0.493 |
HRF | 0.001 | 0.000 | 0.004 | 0.483 | 0.103 | 0.022 |
SHRM | 0.000 | 0.000 | 0.187 | 0.767 | −0.034 | 0.453 |
Drusen | 0.000 | 0.000 | 0.059 | 0.978 | 0.068 | 0.132 |
Volumes and Age

Volumes and Race/Ethnicity

Presence of IRF and SRF at Baseline
Parameter | First-Treated Eye (Total n = 2473 Eyes) | Second-Treated Eye (Total n = 493 Eyes) |
---|---|---|
IRF [n, (%)] | 1653 (66.8) | 297 (60.2) |
SRF [n, (%)] | 2045 (82.7) | 358 (72.6) |
IRF only without SRF [n, (%)] | 301 (12.2) | 105 (21.3) |
SRF only without IRF [n, (%)] | 693 (28.0) | 166 (33.7) |
IRF and SRF [n, (%)] | 1352 (54.7) | 192 (38.9) |
Neither IRF nor SRF [n, (%)] | 127 (5.1) | 30 (6.1) |
Discussion
- Cheong K.X.
- Chong Teo K.Y.
- Ming Cheung G.C.
- Cheong K.X.
- Chong Teo K.Y.
- Ming Cheung G.C.
Study Limitations
Supplementary Data
- Fig S1
- Fig S2
- Fig S3
- Fig S4
- Fig S5
- Table S1
- Table S3
- Table S4
- Table S4
- Table S5
- Table S6
- Table S2
References
- Biomarkers of optical coherence tomography in evaluating the treatment outcomes of neovascular age-related macular degeneration: a real-world study.Sci Rep. 2019; 9: 529
- A paradigm shift in imaging biomarkers in neovascular age-related macular degeneration.Prog Retin Eye Res. 2016; 50: 1-24
- Correlation of 3-dimensionally quantified intraretinal and subretinal fluid with visual acuity in neovascular age-related macular degeneration.JAMA Ophthalmol. 2016; 134: 182-190
- An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration.Am J Ophthalmol. 2007; 143: 566-583
- A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study.Am J Ophthalmol. 2009; 148: 43-58.e1
- Safety and efficacy of a flexible dosing regimen of ranibizumab in neovascular age-related macular degeneration: the SUSTAIN study.Ophthalmology. 2011; 118: 663-671
- A Phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration.Ophthalmology. 2009; 116: 1731-1739
- Errors in retinal thickness measurements obtained by optical coherence tomography.Ophthalmology. 2006; 113: 285-293
- Quantitative comparison of macular segmentation performance using identical retinal regions across multiple spectral-domain optical coherence tomography instruments.Br J Ophthalmol. 2015; 99: 794-800
- Morphologic parameters relevant for visual outcome during anti-angiogenic therapy of neovascular age-related macular degeneration.Ophthalmology. 2014; 121: 1237-1245
- Morphology and visual acuity in aflibercept and ranibizumab therapy for neovascular age-related macular degeneration in the VIEW Trials.Ophthalmology. 2016; 123: 1521-1529
- Predictive value of retinal morphology for visual acuity outcomes of different ranibizumab treatment regimens for neovascular AMD.Ophthalmology. 2016; 123: 60-69
- Subretinal hyperreflective material in the d.Ophthalmology. 2015; 122: 1846-1853.e5
- Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration.Ophthalmology. 2013; 120: 1046-1056
- Identification of fluid on optical coherence tomography by treating ophthalmologists versus a reading center in the comparison of age-related macular degeneration treatments trials.Retina. 2015; 35: 1303-1314
- Computerized assessment of intraretinal and subretinal fluid regions in spectral-domain optical coherence tomography images of the retina.Am J Ophthalmol. 2013; 155: 277-286.e1
- Application of automated quantification of fluid volumes to anti-VEGF therapy of neovascular age-related macular degeneration.Ophthalmology. 2020; 127: 1211-1219
- Automated segmentation of lesions including subretinal hyperreflective material in neovascular age-related macular degeneration.Am J Ophthalmol. 2018; 191: 64-75
- Segmentation of retinal fluid based on deep learning: application of three-dimensional fully convolutional neural networks in optical coherence tomography images.Int J Ophthalmol. 2019; 12: 1012-1020
- Double-branched and area-constraint fully convolutional networks for automated serous retinal detachment segmentation in SD-OCT images.Comput Methods Programs Biomed. 2019; 176: 69-80
- Deep-learning based multiclass retinal fluid segmentation and detection in optical coherence tomography images using a fully convolutional neural network.Med Image Anal. 2019; 54: 100-110
- Deep-learning based, automated segmentation of macular edema in optical coherence tomography.Biomed Opt Express. 2017; 8: 3440-3448
- RETOUCH: the retinal OCT fluid detection and segmentation benchmark and challenge.IEEE Trans Med Imaging. 2019; 38: 1858-1874
- Fully automated detection and quantification of macular fluid in OCT using deep learning.Ophthalmology. 2018; 125: 549-558
- Tolerating subretinal fluid in neovascular age-related macular degeneration treated with ranibizumab using a treat-and-extend regimen: FLUID study 24-month results.Ophthalmology. 2019; 126: 723-734
- Clinically applicable deep learning for diagnosis and referral in retinal disease.Nat Med. 2018; 24: 1342-1350
- Predicting conversion to wet age-related macular degeneration using deep learning.Nat Med. 2020; 26: 892-899
- One- and two-year visual outcomes from the Moorfields age-related macular degeneration database: a retrospective cohort study and an open science resource.BMJ Open. 2019; 9e027441
- Moorfields AMD database report 2: fellow eye involvement with neovascular age-related macular degeneration.Br J Ophthalmol. 2020; 104: 684-690
- Macular thickness measurements in normal eyes with time-domain and Fourier-domain optical coherence tomography.Retina. 2009; 29: 980-987
- Three-dimensional analysis of morphologic changes and visual outcomes in neovascular age-related macular degeneration.Invest Ophthalmol Vis Sci. 2017; 58: 1337-1345
- Relationship between visual acuity and spectral domain optical coherence tomography retinal parameters in neovascular age-related macular degeneration.Ophthalmologica. 2014; 231: 37-44
- Effect of ranibizumab retreatment frequency on neurosensory retinal volume in neovascular AMD.Retina. 2009; 29: 592-600
- Relationship between optical coherence tomography retinal parameters and visual acuity in neovascular age-related macular degeneration.Ophthalmology. 2008; 115: 2206-2214
- Reproducibility of quantitative optical coherence tomography subanalysis in neovascular age-related macular degeneration.Invest Ophthalmol Vis Sci. 2007; 48: 4300-4307
- Morphological and functional characteristics at the onset of exudative conversion in age-related macular degeneration.Retina. 2020; 40: 1070-1078
- Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration.Ophthalmology. 2012; 119: 2537-2548
- Ranibizumab and bevacizumab for neovascular age-related macular degeneration.N Engl J Med. 2011; 364: 1897-1908
- HAWK and HARRIER: phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration.Ophthalmology. 2020; 127: 72-84
- Correspondence: Trends in retina specialist imaging utilization from 2012 to 2016 in the United States Medicare fee-for-service population.Am J Ophthalmol. 2020; 211: 229
- Artificial intelligence in retina.Prog Retin Eye Res. 2018; 67: 1-29
- High-definition medicine.Cell. 2017; 170: 828-843
- Consensus nomenclature for reporting neovascular age-related macular degeneration data: Consensus on Neovascular Age-Related Macular Degeneration Nomenclature Study Group.Ophthalmology. 2020; 127: 616-636
- The estimated prevalence and incidence of late stage age related macular degeneration in the UK.Br J Ophthalmol. 2012; 96: 752-756
- The role of social deprivation in severe neovascular age-related macular degeneration.Br J Ophthalmol. 2014; 98: 1625-1628
- Key drivers of visual acuity gains in neovascular age-related macular degeneration in real life: findings from the AURA study.Br J Ophthalmol. 2016; 100: 1623-1628
- Do we need a new classification for choroidal neovascularization in age-related macular degeneration?.Retina. 2010; 30: 1333-1349
- Polypoidal choroidal vasculopathy: definition, pathogenesis, diagnosis, and management.Ophthalmology. 2018; 125: 708-724
- Macular morphology and visual acuity in the comparison of age-related macular degeneration treatments trials.Ophthalmology. 2013; 120: 1860-1870
- Intraretinal cysts are the most relevant prognostic biomarker in neovascular age-related macular degeneration independent of the therapeutic strategy.Br J Ophthalmol. 2014; 98: 1629-1635
- Macular morphology and visual acuity in the second year of the Comparison of Age-Related Macular Degeneration Treatments Trials.Ophthalmology. 2016; 123: 865-875
- Risk of geographic atrophy in the comparison of age-related macular degeneration treatments trials.Ophthalmology. 2014; 121: 150-161
- Visual acuity at presentation in the second eye versus first eye in patients with exudative age-related macular degeneration.Eur J Ophthalmol. 2016; 26: 44-47
- Intravitreal bevacizumab versus ranibizumab: effects on the vessels of the fellow non-treated eye.J Curr Ophthalmol. 2019; 31: 55-60
- Systemic pharmacokinetics and pharmacodynamics of intravitreal aflibercept, bevacizumab, and ranibizumab.Retina. 2017; 37: 1847-1858
- Subretinal hyperreflective exudation associated with neovascular age-related macular degeneration.Retina. 2014; 34: 1281-1288
- Prognostic value of hyperreflective foci in neovascular age-related macular degeneration treated with bevacizumab.Retina. 2016; 36: 2175-2182
- Relationship between retinal morphological findings and visual function in age-related macular degeneration.Graefes Arch Clin Exp Ophthalmol. 2012; 250: 1129-1136
- Correlation between optical coherence tomographic hyperreflective foci and visual outcomes after anti-VEGF treatment in neovascular age-related macular degeneration and polypoidal choroidal vasculopathy.Retina. 2016; 36: 465-475
- Influence of pigment epithelial detachment on visual acuity in neovascular age-related macular degeneration.Surv Ophthalmol. 2020 May 16; 30087-4 ([Epub ahead of print]): S0039-S6257https://doi.org/10.1016/j.survophthal.2020.05.003
- Response of pigment epithelial detachment to anti-vascular endothelial growth factor treatment in age-related macular degeneration.Am J Ophthalmol. 2016; 166: 112-119
- Pigment epithelial detachment followed by retinal cystoid degeneration leads to vision loss in treatment of neovascular age-related macular degeneration.Ophthalmology. 2015; 122: 822-832
- Quantitative changes in retinal pigment epithelial detachments as a predictor for retreatment with anti-VEGF therapy.Retina. 2013; 33: 459-466
- Baseline predictors of visual acuity outcome in patients with wet age-related macular degeneration.Biomed Res Int. 2018; 2018: 9640131
- Relationship between visual acuity and retinal thickness during anti-vascular endothelial growth factor therapy for retinal diseases.Am J Ophthalmol. 2017; 180: 8-17
- Longitudinal associations between microstructural changes and microperimetry in the early stages of age-related macular degeneration.Invest Ophthalmol Vis Sci. 2016; 57: 3714-3722
- What effect does ethnicity have on the response to ranibizumab in the treatment of wet age-related macular degeneration?.Ophthalmologica. 2018; 240: 157-162
- Sociodemographic factors in neovascular age-related macular degeneration.Ophthalmology. 2020; 127: 280-282
Article Info
Publication History
Publication stage
In Press Journal Pre-ProofFootnotes
Supplemental material available at www.aaojournal.org.
Financial Disclosure(s): The author(s) have made the following disclosure(s): P.A.K.: Consultant – DeepMind, Roche , Novartis, Apellis; Equity owner – Big Picture Medical; Speaker fees – Heidelberg Engineering , Topcon, Allergan , Bayer; Support –Moorfields Eye Charity Career Development Award ( R190028A ); UK Research & Innovation Future Leaders Fellowship ( MR/T019050/1 ).
R.C.: Studentship support – College of Optometrists , United Kingdom; Employee – Google LLC; Stock ownership – Alphabet.
C.J.K., T.X., and M.W.: Employees – Google LLC; Stock ownership – Alphabet.
E.K.: Consultant – Google Health.
P.J.P.: Support – NIHR BRC at Moorfields Eye Hospital; Speaker fees – Bayer, Novartis UK.
K.B.: Consultant – Roche , Novartis; Speaker fees – Novartis , Bayer, Allergan , Alimera, Topcon, Heidelberg Engineering .
Supported by Macular Society Grant Award Number 179050 , Moorfields Eye Charity Career Development Award (R190028A), and UK Research & Innovation Future Leaders Fellowship (MR/T019050/1).
P.A.K. and R.C. jointly supervised the work.
HUMAN SUBJECTS: Human subjects were included in this study. Review and analysis of retrospective anonymized data was approved by the Moorfields Eye Hospital Institutional Review Board. All research adhered to the tenets of the Declaration of Helsinki. All participants provided informed consent.
No animal subjects were used in this study.
Author Contributions:
Conception and design: Moraes, Fu, Wilson, Khalid, Wagner, Korot, Ferraz, Faes, Kelly, Spitz, Patel, Balaskas, Keenan, Keane, Chopra
Data collection: Moraes, Fu, Wilson, Khalid, Wagner, Korot, Ferraz, Faes, Kelly, Spitz, Patel, Balaskas, Keenan, Keane, Chopra
Analysis and interpretation: Moraes, Fu, Wilson, Khalid, Wagner, Korot, Ferraz, Faes, Kelly, Spitz, Patel, Balaskas, Keenan, Keane, Chopra
Obtained funding: Patel, Keane, Chopra
Overall responsibility: Moraes, Fu, Wilson, Khalid, Wagner, Korot, Ferraz, Faes, Kelly, Spitz, Patel, Balaskas, Keenan, Keane, Chopra
Identification
Copyright
User License
Creative Commons Attribution (CC BY 4.0) |
Permitted
- Read, print & download
- Redistribute or republish the final article
- Text & data mine
- Translate the article
- Reuse portions or extracts from the article in other works
- Sell or re-use for commercial purposes
Elsevier's open access license policy